CAPTRUST Financial Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

CAPTRUST Financial Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$131K	Buy	+10,233	New	+$132K	﹤0.01%	2989
2022 Q2	–	Hold	0	–	–	–	5146
2022 Q1	–	Hold	0	–	–	–	5131

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ishara Investments Los Angeles, California $136M AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CAPTRUST Financial Advisors's TNXP Position: Q2 2026 in Review

CAPTRUST Financial Advisors opened a new position in Tonix Pharmaceuticals (TNXP) in Q2 2026: 10,233 shares worth $131K. The stake represents ﹤0.01% of the portfolio and ranks #2989 among its holdings.

102 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

CAPTRUST Financial Advisors held 10,233 shares of Tonix Pharmaceuticals worth $131K as of Q2 2026.
Tonix Pharmaceuticals was a new CAPTRUST Financial Advisors position in Q2 2026.
Tonix Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2989 holding.
102 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.